Spyre Therapeutics: Why Insiders Are Cashing Out Amidst a $5 Billion Valuation

Related Articles

Executive Exodus: Why GLOBALFOUNDRIES Insiders Are Cashing Out

3 months ago

TransDigm: Why Insiders Are Cashing Out After Exercising Options

2 months ago

What Do Recent Insider Sales at Spyre Therapeutics Signal

6 months ago

Insight's Strategic Exit: Why a Major Investor is Cashing Out of Hinge Health

3 months ago

Category

You may also like

Stock News•1 week ago

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock

Spyre Therapeutics priced a $350.0M public offering of 4,117,648 shares at $85.00 each, with a 30-day option for up to ~$52.5M more, expected to close on or about October 7, 2026.

SYRE

Share

Stock News•3 weeks ago

Insider Sale: CEO Liquidates Nearly 40,000 Shares of Small-Cap Growth Stock

A CEO sold 39,103 shares at a weighted average price of $37.71, totaling ~$1.5 million, equal to 5% of their direct Class A stake. The transaction reduces insider ownership and may draw investor scrut...

IBTA

Share

Stock News•3 months ago

What This Immunome Sale Means a Day Before a Big FDA Milestone

An Immunome insider sold 100K shares (~$2.4M) on July 6-7, 2026, representing 32% of their holdings, ahead of a major FDA milestone.

IMNM

Share